A growing pool of literature demonstrates that KDM5A is highly expressed in various cancer tissues, including gastric cancer, acute myeloid leukemia, and breast cancer, and proves that KDM5A is a potential molecular biomarker and novel target for cancer therapy [27–29]. This evidence concerns the gene KDM5A and cancer.